194 related articles for article (PubMed ID: 21383911)
1. Bevacizumab in the treatment of ovarian cancer.
Eskander RN; Randall LM
Biologics; 2011; 5():1-5. PubMed ID: 21383911
[TBL] [Abstract][Full Text] [Related]
2. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
4. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
5. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
6. Critical appraisal of bevacizumab in the treatment of ovarian cancer.
Yoshida H; Yabuno A; Fujiwara K
Drug Des Devel Ther; 2015; 9():2351-8. PubMed ID: 25960638
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibition and synthetic lethality in ovarian cancer.
Eskander RN; Tewari KS
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):613-22. PubMed ID: 24984781
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials and future potential of targeted therapy for ovarian cancer.
Itamochi H; Kigawa J
Int J Clin Oncol; 2012 Oct; 17(5):430-40. PubMed ID: 22926640
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
10. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.
McClung EC; Wenham RM
Int J Womens Health; 2016; 8():59-75. PubMed ID: 27051317
[TBL] [Abstract][Full Text] [Related]
11. Current status on biologic therapies in the treatment of epithelial ovarian cancer.
Han ES; Lin P; Wakabayashi M
Curr Treat Options Oncol; 2009 Apr; 10(1-2):54-66. PubMed ID: 19381822
[TBL] [Abstract][Full Text] [Related]
12. The role of bevacizumab in advanced epithelial ovarian cancer.
Kroep JR; Nortier JW
Curr Pharm Des; 2012; 18(25):3775-83. PubMed ID: 22591420
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and advanced-stage ovarian cancer. Yet another oncological indication, but still best to avoid using this drug.
Prescrire Int; 2013 Mar; 22(136):64-7. PubMed ID: 23593688
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab as front-line treatment for newly diagnosed epithelial cancer.
González Martín A; Bratos R; Márquez R; Alonso S; Chiva L
Expert Rev Anticancer Ther; 2013 Feb; 13(2):123-9. PubMed ID: 23406552
[TBL] [Abstract][Full Text] [Related]
18. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
19. Akt-activated endothelium constitutes the niche for residual disease and resistance to bevacizumab in ovarian cancer.
Guerrouahen BS; Pasquier J; Kaoud NA; Maleki M; Beauchamp MC; Yasmeen A; Ghiabi P; Lis R; Vidal F; Saleh A; Gotlieb WH; Rafii S; Rafii A
Mol Cancer Ther; 2014 Dec; 13(12):3123-36. PubMed ID: 25319392
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
